Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF) (2010 - 2026)

Lineage Cell Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $188000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 14.63% year-over-year to $188000.0 in Q1 2026; TTM through Mar 2026 was $723000.0, a 20.9% increase from a year earlier, with the FY2025 full-year figure at $699000.0, up 19.08% from the prior year.
• Depreciation & Amortization (CF) improved to $188000.0 in Q1 2026 per LCTX's latest filing, from $186000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $188000.0 in Q1 2026 and bottomed at $138000.0 in Q1 2023.
• The 5-year median for Depreciation & Amortization (CF) is $146000.0 (2022), against an average of $154000.0.
• Across the five-year window, Depreciation & Amortization (CF) slipped 13.79% in 2022 and grew 26.24% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $141000.0 in 2022, then rose by 1.42% to $143000.0 in 2023, then increased by 5.59% to $151000.0 in 2024, then climbed by 23.18% to $186000.0 in 2025, then climbed by 1.08% to $188000.0 in 2026.
• Per Business Quant, the three latest LCTX Depreciation & Amortization (CF) figures stand at $188000.0 (Q1 2026), $186000.0 (Q4 2025), and $178000.0 (Q3 2025).